UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 12, 2006
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-11397
|
|
33-0628076 |
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer |
incorporation or organization)
|
|
|
|
Identification No.) |
|
|
|
3300 Hyland Avenue |
|
|
Costa Mesa, California
|
|
92626 |
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (714) 545-0100
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events.
On December 12, 2006, Valeant Pharmaceuticals International (Valeant) received a
notice of default (the Notice) from The Bank of New York, as trustee (the Trustee) for the holders
of Valeants 3.0% Convertible Notes due 2010 (the 3.0% Notes), asserting that a default
occurred under the Indenture dated as of November 19, 2003 governing the 3.0% Notes and Valeants 4.0% Convertible Notes due 2013 (the 4.0% Notes). The Notice asserts that a default
occurred under the Indenture when Valeant failed to timely file with the Securities and Exchange
Commission (the Commission) its quarterly report on Form 10-Q for the quarter ended September 30,
2006 (the Form 10-Q).
In the event that the Trustee is successful in asserting that Valeants failure to timely file
the Form 10-Q is a default under the Indenture, such default will become an Event of Default
under the Indenture unless Valeant cures the default within 60 days of receipt of the Notice. If
Valeant fails to cure the default within the prescribed time period and an Event of Default occurs
and is continuing, the Trustee or the holders of at least 25% in aggregate principal amount of
either the 3.0% Notes or the 4.0% Notes outstanding under the Indenture may accelerate the payment
of all unpaid principal of that series, which amount would then become immediately due and payable
in full unless Valeant were able to obtain a waiver of the Event of Default from the holders of a
majority in aggregate principal amount of such series. The unpaid principal amount of the 3.0%
Notes is $240.0 million, and the unpaid principal amount of the 4.0% Notes is also $240.0 million.
While Valeant intends to file the Form 10-Q with the Commission as promptly as practicable
after completion of its previously announced review of its stock option granting practices and
review by its independent registered public accounting firm, Valeant cannot predict at this time
when it will be able to file the Form 10-Q.
Forward-Looking Statements
This current report on Form 8-K contains forward-looking statements, including, but not
limited to, statements regarding the potential consequences of an asserted default under the
Indenture, which are based on Valeants current expectations and involve risks and uncertainties,
including, but not limited to, risks and uncertainties relating to the final interpretation of the
Indenture and Valeants ability to cure any default deemed to have occurred thereunder. Valeant
cautions the reader that actual results could differ materially from the expectations described in
the forward-looking statements. Valeant also cautions the reader that undue reliance should not be
placed on any of the forward-looking statements, which speak only as of the date of this report.
Valeant undertakes no responsibility to update any of these forward-looking statements to reflect
events or circumstances after the date of this report or to reflect actual outcomes.
2.